January 19, 2010

H1N1 Influenza A Update

New York Statewide School Health Services Center

Key Flu Indicators for the Week of January 3 – 9, 2010 from the CDC

During the week of January 3-9, 2010, all key indicators declined compared to the previous week. Below is a summary of the most recent key indicators:

- Visits to doctors for influenza-like illness (ILI) nationally decreased this week over last week. Visits to doctors for ILI also are examined by region. ILI decreased in all 10 regions of the country, but one region (region 9) continues to report elevated activity.
- Overall hospitalization rates are declining.
- The proportion of deaths attributed to pneumonia and influenza (P&I) based on the 122 Cities Report decreased over the previous week and remains below what is expected for this time of year. In addition, another seven flu-related pediatric deaths were reported this week: six of these deaths were associated with laboratory confirmed 2009 H1N1 and one death was associated with an influenza A virus for which the subtype was not determined. Since April 2009, CDC has received reports of 300 laboratory-confirmed pediatric deaths: 255 due to 2009 H1N1, 43 pediatric deaths that were laboratory confirmed as influenza, but the flu virus subtype was not determined, and two pediatric deaths that were associated with seasonal influenza viruses. (Laboratory-confirmed deaths are thought to represent an undercount of the actual number. CDC has provided estimates about the number of 2009 H1N1 cases and related hospitalizations and deaths.
- No states reported widespread influenza activity; a decline of one state from last week. Nine states continue to report regional influenza activity. They are: Alabama, Georgia, Hawaii, Maine, Nevada, New Jersey, New Mexico, New York, and Virginia.



- Almost all of the influenza viruses identified so far continue to be 2009 H1N1 influenza A viruses. These viruses remain similar to the virus chosen for the 2009 H1N1 vaccine, and remain susceptible to the antiviral drugs oseltamivir and zanamivir with rare exception.